In summary, HDAC inhibitors are among the most promising epigenetic radiosensitizers in GBM, with substantial preclinical evidence and emerging clinical data suggesting they can improve outcomes when appropriately combined with radiotherapy (Qiu et al., 2017). The gene discussed is HDAC9; the disease is glioblastoma.